| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Acadia Pharmaceuticals Inc. (ACAD) has 12 insiders with recent SEC Form 4 filings, including 22 buys and 8 sells. ACAD is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 66.1K | $1.88M | - | |
| 10% | 32.0K | $910.6K | - | |
| VP | 19.0K | $540.4K | -16,558 | |
| CEO | 14.8K | $421.1K | - | |
| Other | 13.1K | $372.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2017 | Baity Glenn | EVP And GC | Sale+OE | 31,078 | $35.15 | $1,092,382.38 | -31.7% | |
| Dec 27, 2016 | Baity Glenn | EVP And GC | Sale+OE | 9,800 | $30.46 | $298,473.70 | -12.0% | |
| Dec 20, 2016 | Baity Glenn | EVP And GC | Sale+OE | 10,000 | $30.00 | $300,001.00 | -12.3% | |
| Nov 10, 2016 | Baity Glenn | EVP And GC | Sale+OE | 10,200 | $30.07 | $306,687.48 | -13.9% | |
| Aug 16, 2016 | Harrigan Edmund | Director | Buy | 1,000 | $32.97 | $32,970.00 | New | |
| Aug 10, 2016 | Baker Bros. Advisors LP59 | Director, 10% Owner | Buy | 1,303,030 | $33.00 | $42,999,990.00 | +5.4% | |
| Jul 12, 2016 | Baity Glenn | EVP And GC | Sale+OE | 16,000 | $35.00 | $560,032.77 | -11.3% | |
| Apr 18, 2016 | Iversen Leslie L | Director | Sale+OE | 33,697 | $33.53 | $1,129,998.57 | -48.3% | |
| Apr 1, 2016 | Baker Bros. Advisors LP59 | Director, 10% Owner | Buy | 1,449,090 | $27.08 | $39,239,808.14 | +0.7% | |
| Mar 2, 2016 | Baity Glenn | EVP And GC | Sale+OE | 7,000 | $20.80 | $145,579.70 | -10.0% |